Zevra Therapeutics Inc. (ZVRA) Stock Rises on Q1 2026 Earnings

Zevra Therapeutics Inc. (ZVRA) reported first-quarter 2026 total revenue of $36.2 million, up 77.5% year over year and ahead of the consensus estimate of $32.6 million.

Key financial highlights:

Gross profit of $34.3 million, up 80.1% year over year.

Operating profit of $52.1 million (down 1,072.5% year over year).

Net income attributable to common shareholders of $37.9 million (down 1,322.7% year over year).

Diluted EPS of 0.60, compared with an estimate of 0.0824 (down 1,100.0% year over year).

Balance sheet and cash flow:

Cash and cash equivalents of $95.6 million, up 156.0% year over year.

Cash from operating activities of $5.1 million (down 162.2% year over year).

Purchases of property, plant and equipment of -$261,500 (up 164.1% year over year).

Total liabilities of $72.8 million, down 44.7% year over year.

Cost and estimate notes:

Cost of sales of $1.9 million, up 41.0% year over year.

Revenue exceeded expectations by about $3.6 million.

The stock moved about 1.33% since market close following the release.

Note: This financials data is sourced from a third-party provider and has not been independently verified by Quiver.

Zevra Therapeutics Inc. Insider Trading Activity

Zevra Therapeutics Inc. insiders have traded $ZVRA stock on the open market 8 times in the past 6 months. Of those trades, 0 have been purchases and 8 have been sales.

Here’s a breakdown of recent trading of $ZVRA stock by insiders over the last 6 months:

NEIL F. MCFARLANE (President and CEO) has made 0 purchases and 2 sales selling 105,625 shares for an estimated $978,610.
JOSHUA SCHAFER (CCO) has made 0 purchases and 2 sales selling 13,875 shares for an estimated $126,300.
TIMOTHY J. SANGIOVANNI (SVP, Finance & Corp Controller) has made 0 purchases and 2 sales selling 4,750 shares for an estimated $42,990.
ADRIAN W QUARTEL (Chief Medical Officer) sold 4,533 shares for an estimated $40,035
RAHSAAN THOMPSON (Chief Legal & Compliance) sold 4,080 shares for an estimated $36,009

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API.

Zevra Therapeutics Inc. Hedge Fund Activity

We have seen 78 institutional investors add shares of Zevra Therapeutics Inc. stock to their portfolio, and 85 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

AIGH CAPITAL MANAGEMENT LLC added 1,200,000 shares (+inf%) to their portfolio in Q1 2026, for an estimated $11,184,000
SUSQUEHANNA INTERNATIONAL GROUP, LLP removed 912,419 shares (-75.7%) from their portfolio in Q4 2025, for an estimated $8,175,274
FMR LLC added 758,922 shares (+46.4%) to their portfolio in Q4 2025, for an estimated $6,799,941
CITADEL ADVISORS LLC added 651,058 shares (+339.5%) to their portfolio in Q4 2025, for an estimated $5,833,479
MORGAN STANLEY added 601,963 shares (+108.3%) to their portfolio in Q4 2025, for an estimated $5,393,588
BLACKROCK, INC. added 469,897 shares (+11.6%) to their portfolio in Q4 2025, for an estimated $4,210,277
ALGERT GLOBAL LLC removed 418,550 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $3,750,208

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API.